We would like to thank our readers, subscribers and collaboration partners for a fruitful, eventful and fun Q1 + Q2 2019, and we wish you all a most wonderful summer!
Nordic Life Science
NLS News
We would like to thank our readers, subscribers and collaboration partners for a fruitful, eventful and fun Q1 + Q2 2019, and we wish you all a most wonderful summer!
Quanterix Corporation has entered into a definitive agreement to acquire privately held UmanDiagnostics AB for $22.5 million, comprised of $16 million in cash plus $6.5 million in Quanterix common stock.
The Board of the national non-profit association for the life science industry in Sweden, SwedenBIO, has appointed Helena Strigård as their new CEO. Strigård will start her new position on
The company has entered into a License Agreement providing Asieris Meditech with a world-wide license to develop and commercialize Cevira for the treatment of HPV induced cervical precancerous lesions. Asieris
The Indian consulting company, Wayinia, has opened an office in Medicon Village, the life science research park in Lund. The company aim is to help Scandinavian healthcare and medtech companies
The company has announced plans to open a third manufacturing facility located in Tilburg, Netherlands. The company currently has sites in the United States and Japan. Fujifilm’s investment in this
The Helsinki University Hospital in Finland has received significant funding from the renowned Wings for Life Foundation to continue its research into spinal cord injury rehabilitation using Nexstim’s SmartFocus technology.
The United States Food and Drug Administration has cleared DigniCap Delta for use by U.S. health care providers. The new device is the fourth generation of The DigniCap Scalp Cooling
Drug and device development
The company announces initial results from its Phase II, randomized, double-blind, placebo-controlled study with sevuparin for the management of acute vaso-occlusive crisis (VOC) in patients with sickle cell disease. Data
The company has announced positive overall survival (OS) results from the Phase III CASPIAN trial with Imfinzi in 1st-line extensive-stage small cell lung cancer (SCLC). A planned interim analysis conducted
The company has announced that the first patient has been enrolled in the fimaChem RELEASE study with registration intent in inoperable bile duct cancer patients. The pivotal RELEASE study has
The company has submitted clinical trial authorization (CTA) application to initiate a Phase I study of its fully owned 4-1BB antibody ATOR-1017 for the treatment of metastasizing cancer. ATOR-1017 is
The company has announced the publication of the first data from two parallel Phase l/lla clinical trials of its lead product candidate BI-1206 as single agent and/or in combination with
Pharmaceutical waste
Pharmaceuticals in the environment is a growing problem of global concern. Drugs taken by humans and animals find their way into rivers, lakes and even drinking water and can have
IVL Swedish Environmental Research Institute and Simrishamn Municipality have tested a completley new treatment system that has now been added to the Stengården sewage plant in Simrishamn, Sweden. “Removing pharmaceutical
Nordic efforts to prevent pharmaceuticals affecting the environment include Danish management of hospital wastewater and a Swedish large-scale sewage plant for removal of pharmaceutical residues. Wastewater from hospitals can contain
“Removing pharmaceutical residues from the water means great environmental advantages. If we succeed we will have an innovative export product which can benefit the environment around the world.”
STAFFAN FILIPSSON, IVL
The Nobel Prize
Professor Honjo did not set out to find a cure for cancer but he is glad he did not give up and believes cancer immunotherapy will be the Number One
When your passion and lifelong work are the same. Great things can happen. Just ask James Allison.
The 2018 Nobel Prize in Medicine was awarded to James P. Allison and Tasuku Honjo for ther pioneering work in cancer immunotheraphy.
“Immunotherapy can be combined with almost anything; you can combine it with chemotherapy or radiation as long as you do it right. The benefits of immunotherapy are several; the best one is that once T cells see something different about the cancer cell and attack the cancer, they can be re-activated [if the cancer reoccurs.]” – James Allison
Upcoming events
This year’s NLSDays will take place at Malmömässan and the aim is to have a broad Nordic participation, where all countries are well represented. Jonas Ekstrand, Director General at SwedenBIO,
A place for startups, established biotech and entrepreneurs to search for finance, pharma and development partners. This event states that it highlights innovation and promotes new business relationships by bringing
This 14th edition of the event will, as always, showcase seminars, one-to-one meetings, exhibitions and lots of networking opportunities. The event which gathers more than 500 representatives from the industry,
BioJapan has played an important role in facilitating interaction between Japanese and global companies/organizations and stimulating new business opportunities for almost two decades. Top business development, licensing, and alliance management
In a new job
Gitte Aabo will step down as President and CEO after 27 years in the company, and 11 of these as CEO, and the Board of Directors has appointed Catherine Mazzacco
The Board of the national non-profit association for the life science industry in Sweden, SwedenBIO, has appointed Helena Strigård as their new CEO. Strigård will start her new position on
Lena Söderström, who was previously in charge at Senzime, is the new chairman of the board of directors of the Umeå-based company Inficure Bio. Lena Söderström has worked in the
Careers
As an industrial PhD student, you get a unique chance to gain a deeper understanding of the industry and obtain valuable experience to bring to your future career. Industrial PhD
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
The company has announced positive overall survival (OS) results from the Phase III CASPIAN trial with Imfinzi in 1st-line extensive-stage small cell lung cancer (SCLC). A planned interim analysis conducted
The company has announced that the first patient has been enrolled in the fimaChem RELEASE study with registration intent in inoperable bile duct cancer patients. The pivotal RELEASE study has
The company has submitted clinical trial authorization (CTA) application to initiate a Phase I study of its fully owned 4-1BB antibody ATOR-1017 for the treatment of metastasizing cancer. ATOR-1017 is
The company has announced the publication of the first data from two parallel Phase l/lla clinical trials of its lead product candidate BI-1206 as single agent and/or in combination with
The company has announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association (EHA) Annual Congress in Amsterdam, showing Calquence (acalabrutinib) significantly prolonged the
The company has completed and announces positive results from the its Phase I/II clinical trial examining the safety and tolerability of the lead candidate, ilixadencel, in combination with tyrosine kinase
Findings presented from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance (empagliflozin 25 mg) in PIONEER 2 and oral semaglutide 14 mg versus Victoza (liraglutide 1.8
Data from the company’s Phase 1/2 O-12-M1 clinical study of lead candidate melflufen demonstrate that melflufen may offer positive disease stabilization and favorable time to next treatment (TTNT) outcomes in heavily-pretreated
The company has completed treatment of 25% of patients in the STAR trial of its medical device, SiPore15, and is well on track to finalize results by Q4 of this
The latest research news from the Nordic region
Science Article
The TEDDY study – which includes kids in Finland and Sweden – is finding factors that influence type 1 diabetes. Type 1 diabetes (T1D), which is often diagnosed in childhood,
Scientists at Washington University School of Medicine and Umeå University have found a molecular compound that prevents and even reverses resistance to the most widely used antibiotic for treating tuberculosis
Radforsk, the Radium Hospital Research Foundation, is awarding several NOK 4.5 million to new research that fights cancer with light, reports Elisabeth Kirkeng Andersen, Oslo Cancer Cluster. Radforsk is an evergreen
Immunotherapy is the 2016 Clinical Cancer Advance of the Year and a promising new strategy for treating cancer. But how far have we come? The American Society of Clinical Oncology
We asked the new Minister about her goals and efforts when it comes to the country’s life science industry and Sweden’s status as an innovation and scientific research nation. How
The European Parliament has voted to end daylight saving time in EU member states. The biannual clock changes will come to an end in 2021 when individual member states will